Skip to main content
COMPLICATED CASE HISTORIES

Lithium-Induced Nephropathies

Psychopharmacology Bulletin 40(2): 134-149, 2007/05/07; https://doi.org/10.64719/pb.4127

Abstract

Lithium, an alkali metal, remains the gold-standard of the pharmacological treatment of bipolar disorder. Over the past decades, the potential of lithium to cause renal damage has been an issue of debate. Polyuria, polydipsia, and, to a lesser degree, nephrogenic diabetes insipidus are frequently observed under treatment with lithium. The glomerular filtration rate (GFR) decreases progressively in a smaller proportion of subjects after several years of treatment with lithium. An even smaller number of patients continue to develop renal insufficiency, ultimately leading to hemodialysis in a small minority of subjects exposed to lithium. So far, no tests exist to identify subjects at risk of lithium-induced nephropathy at an early stage. Therefore, regular monitoring of creatinine and creatinine clearance are recommended in all subjects taking lithium. Psychopharmacology Bulletin. 2007;40(2):134-149.

Access This Article

Choose an access option below to view the full article.

Subscriber Access

If you or your institution has a subscription, log in to access this article.

Log In

Purchase Article

Buy single-article access with a one-time purchase.

$30.00
Add to Cart

How to Cite

Thomas J. Raedler, MD and Klaus Wiedemann, MD. Lithium-Induced Nephropathies. Psychopharmacology Bulletin. 2007/05/07; 40(2):134-149. https://doi.org/10.64719/pb.4127